ArticleAnnals of surgical oncology2025
Propensity Score-Matched Analysis of Liver Venous Deprivation and Portal Vein Embolization Before Planned Hepatectomy in Patients with Extensive Colorectal Liver Metastases and High-Risk Factors for Inadequate Regeneration.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of liver venous deprivation vs portal vein embolization in treating liver cancer with an insufficient liver remnant.Journal of the Chinese Medical Association : JCMA · 2025Pooled it
- When is enough enough?-predicting adequacy of portal vein embolization for hypertrophy of the future liver remnant in the age of liver venous deprivation.Hepatobiliary surgery and nutrition · 2026Article
- Impact of portal vein embolisation uses in colorectal liver metastases: evidence from a rapid review.BMJ open · 2026Review
- How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.Cancers · 2026Review
- Enhancing future liver remnant hypertrophy: innovative preoperative strategies and emerging technologies.Translational gastroenterology and hepatology · 2026Review
- Should all patients be offered liver venous deprivation for insufficient future liver remnant hypertrophy prior to major hepatectomy?Hepatobiliary surgery and nutrition · 2025Article
- Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu.Annals of surgical oncology · 2025Review
- Liver regeneration after partial hepatectomy: Triggers and mechanisms.World journal of hepatology · 2025Review
- Associations of KRAS Point Mutations with Survival of Patients Who Underwent Curative-Intent Resection of Colorectal Liver Metastases.Annals of surgical oncology · 2025Article
- Associations of KRAS Point Mutations with Survival of Patients Who Underwent Curative-Intent Resection of Colorectal Liver Metastases.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver venous deprivation (LVD) is known to induce better future liver remnant (FLR) hypertrophy than portal vein embolization (PVE). The role of LVD, compared with PVE, in inducing FLR hypertrophy and allowing safe hepatectomy for patients with extensive colorectal liver metastases (CLM) and high-risk factors for inadequate hypertrophy remains unclear.
methodsPatients undergoing LVD (n = 22) were matched to patients undergoing PVE (n = 279) in a 1:3 ratio based on propensity scores, prior to planned hepatectomy for CLM at a single center (1998-2023). The propensity scores accounted for high-risk factors for inadequate hypertrophy, namely pre-procedure standardized FLR (sFLR), body mass index, number of systemic therapy cycles, an extension of PVE to segment IV portal vein branches, prior resection, and chemotherapy-associated liver injury.
resultsThe matched cohort included 78 patients (LVD, n = 22; PVE, n = 56). Baseline characteristics were comparable. The number of tumors in the whole liver was similar but more LVD patients had five or more tumors in the left liver (32% vs. 11%; p = 0.024). Post-procedure sFLR was similar but LVD patients had a significantly higher degree of hypertrophy (16% vs. 11%; p = 0.017) and kinetic growth rate (3.9 vs. 2.4% per week; p = 0.006). More LVD patients underwent extended right hepatectomy (93% vs. 55%; p = 0.008). Only one patient had postoperative hepatic insufficiency after PVE, and no patients died within 90 days of hepatectomy.
conclusionIn patients with extensive CLM and high-risk factors, LVD is associated with better FLR hypertrophy compared with PVE and allows for safely performing curative-intent extended major hepatectomy.
Indexed as
Identifiers
39633174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.